Targeting RNA-Binding Oncofetal Protein IGF2BP3: Discovery of Potent and Selective Inhibitors
Journal of Medicinal Chemistry · 13.08.2026 · 69 (15) · 18592-18607
DOI: 10.1021/acs.jmedchem.6c00965 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 15.07.2026. Verfasst von Georgia M Scherer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biochemistry, University of California, Los Angeles, Los Angeles, California90095, United States. Hauptthemen laut MEDLINE: RNA-Binding Proteins, Drug Discovery, Antineoplastic Agents. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, NCRR NIH HHS.
Abstract (Originalsprache)
Cancer remains a major global health burden and a leading cause of death worldwide, despite remarkable advances in cancer biology and therapeutics. RNA-binding proteins (RBPs) are an ideal target for cancer therapies due to their pivotal role in regulating gene expression. However, these proteins are notoriously difficult to target with small molecules, often being considered “undruggable”. IGF2BP3 is one such protein, with a well-established oncogenic role across cancer types and cancer-specific expression patterns. Despite extensive biological evaluation of this protein over the last 30 years, efforts to develop a small-molecule inhibitor for this challenging, yet critical, target have only been rarely reported. We report a structure-activity relationship (SAR) campaign that allowed us to evaluate 37 analogs of I3IN-002, a compound previously shown to bind IGF2BP3. I3IN-002 and three of the most promising compounds identified were evaluated by a cellular thermal shift assay (CETSA) with results consistent with in-cell target engagement. Pharmacokinetic properties for these four compounds were also evaluated. Beyond enabling the discovery of several new potent and selective small molecules, these studies have allowed us to elucidate key parameters for potency, selectivity, and metabolic stability that should aid future efforts in RBP drug discovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Biochemistry, University of California, Los Angeles, Los Angeles, California90095, United States.
- Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, California90095, United States.
- Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California90095, United States.
- Broad Stem Cell Research Center, University of California, Los Angeles, Los Angeles, California90095, United States.
ORCID-Profile: Georgia M Scherer, Stuart J Conway, Neil K Garg
Förderung
- NCI NIH HHS
- NIH HHS
- NCRR NIH HHS
- Division of Graduate Education
- Division of Chemistry
- Jonsson Comprehensive Cancer Center, University of California, Los Angeles
- California Institute of Regenerative Medicine
- ORIP NIH HHS
Zitieren
APA
Scherer, G. M., Sorrentino, J. P., Jaiswal, A. K., Thaxton, M., Brodie, G., Conway, S. J., Rao, D. S., & Garg, N. K. (2026). Targeting RNA-Binding Oncofetal Protein IGF2BP3: Discovery of Potent and Selective Inhibitors. Journal of Medicinal Chemistry, 69(15), 18592-18607. https://doi.org/10.1021/acs.jmedchem.6c00965
Vancouver
Scherer GM, Sorrentino JP, Jaiswal AK, Thaxton M, Brodie G, Conway SJ, et al. Targeting RNA-Binding Oncofetal Protein IGF2BP3: Discovery of Potent and Selective Inhibitors. Journal of Medicinal Chemistry. 2026;69(15):18592-18607. doi:10.1021/acs.jmedchem.6c00965
BibTeX
@article{Scherer2026,
author = {Scherer, Georgia M and Sorrentino, Jacob P and Jaiswal, Amit K and Thaxton, Michelle and Brodie, Glen and Conway, Stuart J and Rao, Dinesh S and Garg, Neil K},
title = {Targeting RNA-Binding Oncofetal Protein IGF2BP3: Discovery of Potent and Selective Inhibitors},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {15},
pages = {18592--18607},
doi = {10.1021/acs.jmedchem.6c00965}
}
EUVIMED